All In MedTech

Device Trial Radar · NCT04857268

Diagnostic Validation of Wearable ECG Monitoring Patch, ATP-C120

Diagnostic Validation of Wearable Continuous ECG Monitoring Patch, ATP-C120, in High Risk Patients for New-onset Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

320

Actual

Start

Nov 13, 2020

Primary completion

Apr 30, 2022

Study completion Apr 30, 2023

Sponsor

Lead sponsor
Seoul National University Bundang HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kyungpook National University Hospital
First posted
Apr 23, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A new wearable patch-type device, ATP-C120 (ATsens, Seongnam, Korea) is a novel, single-lead ECG monitoring device and can continuously monitor the ECG signal for upto 11 days. This study is designed to experiment its diagnostic capability of new-onset atrial fibrillation in high risk patients. Several studies reported that validated CHA2DS2-VASc score has high performance in predicting new-onset atrial fibrillation and there are over 10 percent of new-onset atrial fibrillation in patients whose calculated CHA2DS2-VASc scores are ≥ 2. Thus, through this study, the investigators sought to evaluate the validation of early detection of new-onset atrial fibrillation by ATP-C120.

Conditions

  • Atrial Fibrillation New Onset

Interventions

  • wearable continuous ECG monitoring patch, ATP-C120Device

    ATP-C120 is a novel, single-lead ECG monitoring device which can continuously monitor the ECG signal as long as 14 days (11 days if the device is connected to the smartphone via Bluetooth) when attached to skin adjacent to the heart of patients. It weighs about 8.3 g, with a size of 84 × 39 × 8.3 mm. When the device is attached to the patient, several predefined methods were utilized to prevent the occurrence of noise or signal loss. First, the skin was cleansed and disinfected using a 70% ethanol solution. Skin hair was removed if needed. Then the protection film was removed from the patient-side surface of the device. The device is placed at the left 3rd intercostal space 45 degrees tilted toward the inside.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of new-onset atrial fibrillationTime frame: 11 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kyungpook National University Hospital

    Daegu, South Korea

  • Seoul National Universtiy Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.